Our Chief Innovator
Mir Imran founded InCube Labs to focus on his passion: creating medical solutions that change the standard of care in critical healthcare markets. After attending medical school, Mir began his career as a healthcare entrepreneur in the late 1970’s and has founded numerous game-changing companies since those early days.
MORE ON MIROur Leaders
InCube Labs’ team has expertise across a range of disciplines: pharmacology and physiology, protein and polymer chemistry, tissue engineering, mechanical engineering and material science, electronics and software, industrial design, clinical development and manufacturing. Our leadership team also has deep experience in company building and commercializing innovations.
Mir Imran
Mir Imran
Chairman & CEO
Mir Imran
Chairman & CEOMir Imran is a prolific healthcare innovator and entrepreneur who has been developing and commercializing breakthrough medical innovations for more than 40 years. Since 1995, Mir’s innovations have been developed at his life science R&D lab and incubator, InCube Labs. As an entrepreneur, Mir has founded more than 20 life sciences companies; 15 of his companies have seen “liquidity events” (IPO/Acquisition). Mir now holds more than 400 issued patents and is perhaps most well-known for his pioneering contributions to the first FDA-approved Automatic Implantable Cardioverter Defibrillator. Mir has received a number of industry accolades for his work including being named one of the most inspiring people in life sciences (PharmaVoice) and one of the “Top 50 Medical Device Inventors of All Time” (QMed). Mir has also been recognized as a fellow for both the National Academy of Inventors (NAI) and the National Academy of Engineering (NAE). He holds an M.S. in bioengineering and a B.S. in electrical engineering from Rutgers. Mir also attended CMDNJ/Rutgers Medical School. In addition to leading InCube Labs, Mir is also the Chairman and CEO of InCube company, Rani Therapeutics.
Phil Morgan
Phil Morgan
Vice President (San Antonio)
Phil Morgan
Vice President (San Antonio)Phil Morgan brings more than 25 years of pharmaceutical research and development experience to InCube Labs and has extensive experience in drug development and the regulatory approval process.
He was the pre-clinical pharmacology expert for several drugs including Wellbutrin SR and Zyban. Prior to joining InCube Labs, Phil co-founded several successful life science companies and served as the president and CEO of Cytospect, Cytoscan and Neurotherapeutics.
Before that, he was the Head of the Department of Molecular Pharmacology and a Senior Scientist at GlaxoSmithKline and a Visiting Fellow and Scientist at the National Institutes of Health, Bethesda, MD. Phil has published over 50 peer-reviewed articles and holds a PhD from London University and an MBA from Duke University.
Mike Billig
Mike Billig
Vice President, Regulatory Affairs
Mike Billig
Vice President, Regulatory AffairsMike serves as Vice President, Regulatory. In addition to his work with InCube, Mike is CEO of Experien Group, a clinical and regulatory consulting firm, which he co-founded in 2003. His entire 35+ year professional career has been involved with regulatory affairs, quality systems, clinical research, and general management for medical device companies. Mike has secured regulatory approval for hundreds of medical device products across the U.S., Europe, Canada, Central and South America, and Asia. Mike earned his BS degree in Microbiology from the University of Minnesota.
Our Mission
Innovation
We are focused on developing and commercializing disruptive innovations that solve problems in a new way and have the potential for big impact
Commitment
We are committed as a team to work collaboratively together across disciplines to achieve common goals and advance our companies
Compassion
We are motivated by our desire to improve the lives of millions of patients suffering from chronic disease
Our Focus
InCube’s innovation process has been developed over years of examining and understanding problems. After years of building companies, Mir evaluated his successes and failures, and devised a process for innovation. We focus on the big problems and developing disruptive innovations which can have a major impact on patients and markets. This focus is the lifeblood of our organization, and central to our work every day.